nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—Corticosteroid Hormone Receptor Agonists—Prednisone—systemic scleroderma	0.261	1	CiPCiCtD
Fluocinonide—Mometasone—systemic scleroderma	0.224	1	CrCtD
Fluocinonide—psoriasis—systemic scleroderma	0.217	1	CtDrD
Fluocinonide—NR3C1—Mometasone—systemic scleroderma	0.0699	0.759	CbGbCtD
Fluocinonide—NR3C1—Prednisone—systemic scleroderma	0.0223	0.241	CbGbCtD
Fluocinonide—Fluticasone furoate—Mometasone—systemic scleroderma	0.0069	0.0395	CrCrCtD
Fluocinonide—Flumethasone Pivalate—Mometasone—systemic scleroderma	0.0062	0.0355	CrCrCtD
Fluocinonide—Difluprednate—Mometasone—systemic scleroderma	0.006	0.0344	CrCrCtD
Fluocinonide—Halobetasol Propionate—Mometasone—systemic scleroderma	0.006	0.0344	CrCrCtD
Fluocinonide—Fluticasone Propionate—Mometasone—systemic scleroderma	0.006	0.0344	CrCrCtD
Fluocinonide—Clocortolone—Mometasone—systemic scleroderma	0.00565	0.0323	CrCrCtD
Fluocinonide—Beclomethasone—Mometasone—systemic scleroderma	0.00565	0.0323	CrCrCtD
Fluocinonide—Fluocortolone—Mometasone—systemic scleroderma	0.00548	0.0314	CrCrCtD
Fluocinonide—Fluocinolone Acetonide—Mometasone—systemic scleroderma	0.00533	0.0305	CrCrCtD
Fluocinonide—Budesonide—Mometasone—systemic scleroderma	0.00519	0.0297	CrCrCtD
Fluocinonide—Amcinonide—Mometasone—systemic scleroderma	0.00519	0.0297	CrCrCtD
Fluocinonide—Flunisolide—Mometasone—systemic scleroderma	0.00505	0.0289	CrCrCtD
Fluocinonide—Desonide—Mometasone—systemic scleroderma	0.00505	0.0289	CrCrCtD
Fluocinonide—Diflorasone—Mometasone—systemic scleroderma	0.00505	0.0289	CrCrCtD
Fluocinonide—Clobetasol propionate—Mometasone—systemic scleroderma	0.00505	0.0289	CrCrCtD
Fluocinonide—Paramethasone—Mometasone—systemic scleroderma	0.00493	0.0282	CrCrCtD
Fluocinonide—Desoximetasone—Mometasone—systemic scleroderma	0.00481	0.0275	CrCrCtD
Fluocinonide—Fluorometholone—Mometasone—systemic scleroderma	0.00469	0.0269	CrCrCtD
Fluocinonide—Triamcinolone—Mometasone—systemic scleroderma	0.00469	0.0269	CrCrCtD
Fluocinonide—Fluprednidene Acetate—Mometasone—systemic scleroderma	0.00469	0.0269	CrCrCtD
Fluocinonide—Rimexolone—Mometasone—systemic scleroderma	0.00459	0.0262	CrCrCtD
Fluocinonide—Dexamethasone—Mometasone—systemic scleroderma	0.00459	0.0262	CrCrCtD
Fluocinonide—Betamethasone—Mometasone—systemic scleroderma	0.00459	0.0262	CrCrCtD
Fluocinonide—Methylprednisolone—Mometasone—systemic scleroderma	0.00439	0.0251	CrCrCtD
Fluocinonide—Ciclesonide—Prednisone—systemic scleroderma	0.00391	0.0224	CrCrCtD
Fluocinonide—Fluocortolone—Prednisone—systemic scleroderma	0.00299	0.0171	CrCrCtD
Fluocinonide—Budesonide—Prednisone—systemic scleroderma	0.00283	0.0162	CrCrCtD
Fluocinonide—Amcinonide—Prednisone—systemic scleroderma	0.00283	0.0162	CrCrCtD
Fluocinonide—Diflorasone—Prednisone—systemic scleroderma	0.00276	0.0158	CrCrCtD
Fluocinonide—Flunisolide—Prednisone—systemic scleroderma	0.00276	0.0158	CrCrCtD
Fluocinonide—Clobetasol propionate—Prednisone—systemic scleroderma	0.00276	0.0158	CrCrCtD
Fluocinonide—Desonide—Prednisone—systemic scleroderma	0.00276	0.0158	CrCrCtD
Fluocinonide—Paramethasone—Prednisone—systemic scleroderma	0.00269	0.0154	CrCrCtD
Fluocinonide—Desoximetasone—Prednisone—systemic scleroderma	0.00262	0.015	CrCrCtD
Fluocinonide—Fluorometholone—Prednisone—systemic scleroderma	0.00256	0.0146	CrCrCtD
Fluocinonide—Triamcinolone—Prednisone—systemic scleroderma	0.00256	0.0146	CrCrCtD
Fluocinonide—Mometasone—Prednisone—systemic scleroderma	0.00256	0.0146	CrCrCtD
Fluocinonide—Fluprednidene Acetate—Prednisone—systemic scleroderma	0.00256	0.0146	CrCrCtD
Fluocinonide—Rimexolone—Prednisone—systemic scleroderma	0.0025	0.0143	CrCrCtD
Fluocinonide—Dexamethasone—Prednisone—systemic scleroderma	0.0025	0.0143	CrCrCtD
Fluocinonide—Betamethasone—Prednisone—systemic scleroderma	0.0025	0.0143	CrCrCtD
Fluocinonide—Methylprednisolone—Prednisone—systemic scleroderma	0.00239	0.0137	CrCrCtD
Fluocinonide—Secondary adrenocortical insufficiency—Mometasone—systemic scleroderma	0.00166	0.0554	CcSEcCtD
Fluocinonide—Dermatitis perioral—Mometasone—systemic scleroderma	0.00127	0.0424	CcSEcCtD
Fluocinonide—Telangiectasia—Mometasone—systemic scleroderma	0.00122	0.0408	CcSEcCtD
Fluocinonide—Acneiform eruption—Mometasone—systemic scleroderma	0.00114	0.0381	CcSEcCtD
Fluocinonide—Miliaria—Mometasone—systemic scleroderma	0.000979	0.0327	CcSEcCtD
Fluocinonide—Secondary infection—Mometasone—systemic scleroderma	0.000979	0.0327	CcSEcCtD
Fluocinonide—Skin atrophy—Mometasone—systemic scleroderma	0.000953	0.0318	CcSEcCtD
Fluocinonide—Skin striae—Mometasone—systemic scleroderma	0.000905	0.0302	CcSEcCtD
Fluocinonide—Cushing's syndrome—Mycophenolic acid—systemic scleroderma	0.000876	0.0293	CcSEcCtD
Fluocinonide—Dermatitis acneiform—Mometasone—systemic scleroderma	0.000843	0.0282	CcSEcCtD
Fluocinonide—Allergic contact dermatitis—Mometasone—systemic scleroderma	0.000824	0.0275	CcSEcCtD
Fluocinonide—Hypertrichosis—Mometasone—systemic scleroderma	0.000757	0.0253	CcSEcCtD
Fluocinonide—Secondary infection—Azathioprine—systemic scleroderma	0.000751	0.0251	CcSEcCtD
Fluocinonide—Cushing's syndrome—Mycophenolate mofetil—systemic scleroderma	0.000691	0.0231	CcSEcCtD
Fluocinonide—Leukoderma—Mometasone—systemic scleroderma	0.000677	0.0226	CcSEcCtD
Fluocinonide—Secondary adrenocortical insufficiency—Prednisone—systemic scleroderma	0.000613	0.0205	CcSEcCtD
Fluocinonide—Atrophy—Mycophenolic acid—systemic scleroderma	0.00061	0.0204	CcSEcCtD
Fluocinonide—Atrophy—Mycophenolate mofetil—systemic scleroderma	0.000481	0.0161	CcSEcCtD
Fluocinonide—Cushing's syndrome—Prednisone—systemic scleroderma	0.000468	0.0156	CcSEcCtD
Fluocinonide—Folliculitis—Mometasone—systemic scleroderma	0.000458	0.0153	CcSEcCtD
Fluocinonide—Telangiectasia—Prednisone—systemic scleroderma	0.000451	0.0151	CcSEcCtD
Fluocinonide—Acneiform eruption—Prednisone—systemic scleroderma	0.000421	0.0141	CcSEcCtD
Fluocinonide—Cataract subcapsular—Prednisone—systemic scleroderma	0.000407	0.0136	CcSEcCtD
Fluocinonide—Telangiectasia—Methotrexate—systemic scleroderma	0.000377	0.0126	CcSEcCtD
Fluocinonide—Skin atrophy—Prednisone—systemic scleroderma	0.000352	0.0118	CcSEcCtD
Fluocinonide—Skin striae—Prednisone—systemic scleroderma	0.000334	0.0112	CcSEcCtD
Fluocinonide—Atrophy—Prednisone—systemic scleroderma	0.000326	0.0109	CcSEcCtD
Fluocinonide—Dermatitis acneiform—Prednisone—systemic scleroderma	0.000311	0.0104	CcSEcCtD
Fluocinonide—Dermatitis contact—Mometasone—systemic scleroderma	0.000284	0.0095	CcSEcCtD
Fluocinonide—Hypertrichosis—Prednisone—systemic scleroderma	0.00028	0.00935	CcSEcCtD
Fluocinonide—Swelling—Pentoxifylline—systemic scleroderma	0.000274	0.00917	CcSEcCtD
Fluocinonide—Nasal congestion—Pentoxifylline—systemic scleroderma	0.000266	0.00888	CcSEcCtD
Fluocinonide—SMO—connective tissue—systemic scleroderma	0.000257	0.213	CbGeAlD
Fluocinonide—Leukoderma—Prednisone—systemic scleroderma	0.00025	0.00836	CcSEcCtD
Fluocinonide—SMO—skin of body—systemic scleroderma	0.000232	0.192	CbGeAlD
Fluocinonide—Nasal congestion—Mometasone—systemic scleroderma	0.000229	0.00766	CcSEcCtD
Fluocinonide—Leukoderma—Methotrexate—systemic scleroderma	0.000209	0.00698	CcSEcCtD
Fluocinonide—Dermatitis contact—Leflunomide—systemic scleroderma	0.000206	0.00688	CcSEcCtD
Fluocinonide—Nasopharyngitis—Mometasone—systemic scleroderma	0.000187	0.00624	CcSEcCtD
Fluocinonide—SMO—tendon—systemic scleroderma	0.000177	0.147	CbGeAlD
Fluocinonide—Swelling—Mycophenolic acid—systemic scleroderma	0.000164	0.00546	CcSEcCtD
Fluocinonide—SMO—lung—systemic scleroderma	0.000155	0.129	CbGeAlD
Fluocinonide—Immune system disorder—Pentoxifylline—systemic scleroderma	0.000151	0.00506	CcSEcCtD
Fluocinonide—Erythema—Pentoxifylline—systemic scleroderma	0.000146	0.00487	CcSEcCtD
Fluocinonide—Eruption—Methotrexate—systemic scleroderma	0.000144	0.00483	CcSEcCtD
Fluocinonide—Nasal congestion—Lisinopril—systemic scleroderma	0.000143	0.00477	CcSEcCtD
Fluocinonide—Folliculitis—Methotrexate—systemic scleroderma	0.000141	0.00472	CcSEcCtD
Fluocinonide—Dry skin—Leflunomide—systemic scleroderma	0.000139	0.00463	CcSEcCtD
Fluocinonide—Glycosuria—Prednisone—systemic scleroderma	0.000131	0.00439	CcSEcCtD
Fluocinonide—Immune system disorder—Mometasone—systemic scleroderma	0.000131	0.00436	CcSEcCtD
Fluocinonide—Nasopharyngitis—Mycophenolic acid—systemic scleroderma	0.000129	0.00431	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.000123	0.00412	CcSEcCtD
Fluocinonide—Infection—Pentoxifylline—systemic scleroderma	0.000118	0.00395	CcSEcCtD
Fluocinonide—Hyperglycaemia—Leflunomide—systemic scleroderma	0.000118	0.00394	CcSEcCtD
Fluocinonide—Nasopharyngitis—Lisinopril—systemic scleroderma	0.000116	0.00388	CcSEcCtD
Fluocinonide—Skin disorder—Pentoxifylline—systemic scleroderma	0.000116	0.00386	CcSEcCtD
Fluocinonide—Hyperglycaemia—Mycophenolic acid—systemic scleroderma	0.000112	0.00376	CcSEcCtD
Fluocinonide—Infection—Mometasone—systemic scleroderma	0.000102	0.00341	CcSEcCtD
Fluocinonide—Skin exfoliation—Prednisone—systemic scleroderma	0.000102	0.00339	CcSEcCtD
Fluocinonide—Hyperglycaemia—Lisinopril—systemic scleroderma	0.000101	0.00339	CcSEcCtD
Fluocinonide—Immune system disorder—Azathioprine—systemic scleroderma	0.0001	0.00334	CcSEcCtD
Fluocinonide—Immune system disorder—Leflunomide—systemic scleroderma	9.45e-05	0.00316	CcSEcCtD
Fluocinonide—Hyperglycaemia—Mycophenolate mofetil—systemic scleroderma	8.88e-05	0.00297	CcSEcCtD
Fluocinonide—Pain—Mometasone—systemic scleroderma	8.78e-05	0.00293	CcSEcCtD
Fluocinonide—Hypersensitivity—Pentoxifylline—systemic scleroderma	8.77e-05	0.00293	CcSEcCtD
Fluocinonide—SERPINA6—lung—systemic scleroderma	8.55e-05	0.0708	CbGeAlD
Fluocinonide—Skin exfoliation—Methotrexate—systemic scleroderma	8.48e-05	0.00283	CcSEcCtD
Fluocinonide—Pruritus—Pentoxifylline—systemic scleroderma	8.42e-05	0.00281	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	8.15e-05	0.00272	CcSEcCtD
Fluocinonide—Dizziness—Pentoxifylline—systemic scleroderma	7.87e-05	0.00263	CcSEcCtD
Fluocinonide—Erythema—Lisinopril—systemic scleroderma	7.83e-05	0.00261	CcSEcCtD
Fluocinonide—Infection—Azathioprine—systemic scleroderma	7.82e-05	0.00261	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	7.7e-05	0.00257	CcSEcCtD
Fluocinonide—Skin disorder—Azathioprine—systemic scleroderma	7.65e-05	0.00255	CcSEcCtD
Fluocinonide—Rash—Pentoxifylline—systemic scleroderma	7.5e-05	0.00251	CcSEcCtD
Fluocinonide—Dermatitis—Pentoxifylline—systemic scleroderma	7.5e-05	0.0025	CcSEcCtD
Fluocinonide—Headache—Pentoxifylline—systemic scleroderma	7.46e-05	0.00249	CcSEcCtD
Fluocinonide—Infection—Leflunomide—systemic scleroderma	7.39e-05	0.00247	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	7.35e-05	0.00245	CcSEcCtD
Fluocinonide—Nervous system disorder—Leflunomide—systemic scleroderma	7.29e-05	0.00244	CcSEcCtD
Fluocinonide—Pruritus—Mometasone—systemic scleroderma	7.27e-05	0.00243	CcSEcCtD
Fluocinonide—Skin disorder—Leflunomide—systemic scleroderma	7.22e-05	0.00241	CcSEcCtD
Fluocinonide—Dry skin—Prednisone—systemic scleroderma	7.08e-05	0.00236	CcSEcCtD
Fluocinonide—Infection—Mycophenolic acid—systemic scleroderma	7.05e-05	0.00235	CcSEcCtD
Fluocinonide—Nervous system disorder—Mycophenolic acid—systemic scleroderma	6.95e-05	0.00232	CcSEcCtD
Fluocinonide—Skin disorder—Mycophenolic acid—systemic scleroderma	6.89e-05	0.0023	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	6.62e-05	0.00221	CcSEcCtD
Fluocinonide—Rash—Mometasone—systemic scleroderma	6.48e-05	0.00216	CcSEcCtD
Fluocinonide—Dermatitis—Mometasone—systemic scleroderma	6.47e-05	0.00216	CcSEcCtD
Fluocinonide—Headache—Mometasone—systemic scleroderma	6.43e-05	0.00215	CcSEcCtD
Fluocinonide—Pruritus—Captopril—systemic scleroderma	6.38e-05	0.00213	CcSEcCtD
Fluocinonide—Pain—Leflunomide—systemic scleroderma	6.36e-05	0.00212	CcSEcCtD
Fluocinonide—Infection—Lisinopril—systemic scleroderma	6.35e-05	0.00212	CcSEcCtD
Fluocinonide—NR3C1—connective tissue—systemic scleroderma	6.21e-05	0.0514	CbGeAlD
Fluocinonide—Skin disorder—Lisinopril—systemic scleroderma	6.2e-05	0.00207	CcSEcCtD
Fluocinonide—Pain—Mycophenolic acid—systemic scleroderma	6.06e-05	0.00203	CcSEcCtD
Fluocinonide—Hyperglycaemia—Prednisone—systemic scleroderma	6.02e-05	0.00201	CcSEcCtD
Fluocinonide—Dizziness—Captopril—systemic scleroderma	5.96e-05	0.00199	CcSEcCtD
Fluocinonide—Hypersensitivity—Azathioprine—systemic scleroderma	5.8e-05	0.00194	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	5.8e-05	0.00194	CcSEcCtD
Fluocinonide—Rash—Captopril—systemic scleroderma	5.69e-05	0.0019	CcSEcCtD
Fluocinonide—Dermatitis—Captopril—systemic scleroderma	5.68e-05	0.0019	CcSEcCtD
Fluocinonide—NR3C1—smooth muscle tissue—systemic scleroderma	5.68e-05	0.047	CbGeAlD
Fluocinonide—Headache—Captopril—systemic scleroderma	5.65e-05	0.00189	CcSEcCtD
Fluocinonide—NR3C1—skin of body—systemic scleroderma	5.6e-05	0.0464	CbGeAlD
Fluocinonide—Infection—Mycophenolate mofetil—systemic scleroderma	5.56e-05	0.00186	CcSEcCtD
Fluocinonide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	5.49e-05	0.00183	CcSEcCtD
Fluocinonide—Hypersensitivity—Leflunomide—systemic scleroderma	5.48e-05	0.00183	CcSEcCtD
Fluocinonide—Pain—Lisinopril—systemic scleroderma	5.46e-05	0.00183	CcSEcCtD
Fluocinonide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	5.44e-05	0.00182	CcSEcCtD
Fluocinonide—Pruritus—Leflunomide—systemic scleroderma	5.26e-05	0.00176	CcSEcCtD
Fluocinonide—Dizziness—Azathioprine—systemic scleroderma	5.21e-05	0.00174	CcSEcCtD
Fluocinonide—Pruritus—Mycophenolic acid—systemic scleroderma	5.02e-05	0.00168	CcSEcCtD
Fluocinonide—Rash—Azathioprine—systemic scleroderma	4.96e-05	0.00166	CcSEcCtD
Fluocinonide—Dermatitis—Azathioprine—systemic scleroderma	4.96e-05	0.00166	CcSEcCtD
Fluocinonide—Headache—Azathioprine—systemic scleroderma	4.93e-05	0.00165	CcSEcCtD
Fluocinonide—Dizziness—Leflunomide—systemic scleroderma	4.92e-05	0.00164	CcSEcCtD
Fluocinonide—Immune system disorder—Prednisone—systemic scleroderma	4.82e-05	0.00161	CcSEcCtD
Fluocinonide—Pain—Mycophenolate mofetil—systemic scleroderma	4.79e-05	0.0016	CcSEcCtD
Fluocinonide—Hypersensitivity—Lisinopril—systemic scleroderma	4.71e-05	0.00157	CcSEcCtD
Fluocinonide—Dizziness—Mycophenolic acid—systemic scleroderma	4.69e-05	0.00157	CcSEcCtD
Fluocinonide—Rash—Leflunomide—systemic scleroderma	4.69e-05	0.00157	CcSEcCtD
Fluocinonide—Dermatitis—Leflunomide—systemic scleroderma	4.68e-05	0.00156	CcSEcCtD
Fluocinonide—Headache—Leflunomide—systemic scleroderma	4.66e-05	0.00156	CcSEcCtD
Fluocinonide—Erythema—Prednisone—systemic scleroderma	4.65e-05	0.00155	CcSEcCtD
Fluocinonide—Pruritus—Lisinopril—systemic scleroderma	4.52e-05	0.00151	CcSEcCtD
Fluocinonide—NR3C1—digestive system—systemic scleroderma	4.48e-05	0.0371	CbGeAlD
Fluocinonide—Rash—Mycophenolic acid—systemic scleroderma	4.47e-05	0.00149	CcSEcCtD
Fluocinonide—Dermatitis—Mycophenolic acid—systemic scleroderma	4.47e-05	0.00149	CcSEcCtD
Fluocinonide—Headache—Mycophenolic acid—systemic scleroderma	4.44e-05	0.00148	CcSEcCtD
Fluocinonide—NR3C1—tendon—systemic scleroderma	4.27e-05	0.0353	CbGeAlD
Fluocinonide—Dizziness—Lisinopril—systemic scleroderma	4.22e-05	0.00141	CcSEcCtD
Fluocinonide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	4.12e-05	0.00138	CcSEcCtD
Fluocinonide—Immune system disorder—Methotrexate—systemic scleroderma	4.03e-05	0.00135	CcSEcCtD
Fluocinonide—Rash—Lisinopril—systemic scleroderma	4.03e-05	0.00135	CcSEcCtD
Fluocinonide—Dermatitis—Lisinopril—systemic scleroderma	4.02e-05	0.00134	CcSEcCtD
Fluocinonide—Headache—Lisinopril—systemic scleroderma	4e-05	0.00134	CcSEcCtD
Fluocinonide—Pruritus—Mycophenolate mofetil—systemic scleroderma	3.96e-05	0.00132	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.93e-05	0.00131	CcSEcCtD
Fluocinonide—Erythema—Methotrexate—systemic scleroderma	3.88e-05	0.0013	CcSEcCtD
Fluocinonide—Infection—Prednisone—systemic scleroderma	3.77e-05	0.00126	CcSEcCtD
Fluocinonide—NR3C1—lung—systemic scleroderma	3.74e-05	0.031	CbGeAlD
Fluocinonide—Nervous system disorder—Prednisone—systemic scleroderma	3.72e-05	0.00124	CcSEcCtD
Fluocinonide—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.7e-05	0.00124	CcSEcCtD
Fluocinonide—Skin disorder—Prednisone—systemic scleroderma	3.68e-05	0.00123	CcSEcCtD
Fluocinonide—Rash—Mycophenolate mofetil—systemic scleroderma	3.53e-05	0.00118	CcSEcCtD
Fluocinonide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.53e-05	0.00118	CcSEcCtD
Fluocinonide—Headache—Mycophenolate mofetil—systemic scleroderma	3.51e-05	0.00117	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	3.28e-05	0.0011	CcSEcCtD
Fluocinonide—Infection—Methotrexate—systemic scleroderma	3.15e-05	0.00105	CcSEcCtD
Fluocinonide—Nervous system disorder—Methotrexate—systemic scleroderma	3.11e-05	0.00104	CcSEcCtD
Fluocinonide—Skin disorder—Methotrexate—systemic scleroderma	3.08e-05	0.00103	CcSEcCtD
Fluocinonide—Hypersensitivity—Prednisone—systemic scleroderma	2.8e-05	0.000934	CcSEcCtD
Fluocinonide—Pain—Methotrexate—systemic scleroderma	2.71e-05	0.000906	CcSEcCtD
Fluocinonide—Pruritus—Prednisone—systemic scleroderma	2.68e-05	0.000897	CcSEcCtD
Fluocinonide—Dizziness—Prednisone—systemic scleroderma	2.51e-05	0.000838	CcSEcCtD
Fluocinonide—Rash—Prednisone—systemic scleroderma	2.39e-05	0.000799	CcSEcCtD
Fluocinonide—Dermatitis—Prednisone—systemic scleroderma	2.39e-05	0.000798	CcSEcCtD
Fluocinonide—Headache—Prednisone—systemic scleroderma	2.38e-05	0.000794	CcSEcCtD
Fluocinonide—Hypersensitivity—Methotrexate—systemic scleroderma	2.34e-05	0.00078	CcSEcCtD
Fluocinonide—Pruritus—Methotrexate—systemic scleroderma	2.24e-05	0.000749	CcSEcCtD
Fluocinonide—Dizziness—Methotrexate—systemic scleroderma	2.1e-05	0.0007	CcSEcCtD
Fluocinonide—Rash—Methotrexate—systemic scleroderma	2e-05	0.000668	CcSEcCtD
Fluocinonide—Dermatitis—Methotrexate—systemic scleroderma	2e-05	0.000667	CcSEcCtD
Fluocinonide—Headache—Methotrexate—systemic scleroderma	1.99e-05	0.000664	CcSEcCtD
